From the Journals

Study finds higher risk of skin cancer after childhood organ transplant


 

FROM JAMA DERMATOLOGY

A large study showing an increased risk of keratinocyte carcinoma (KC) in children who receive a solid-organ transplant highlights the need for early education about risk reduction and more research to determine optimal timing for screening, say an investigator and two dermatologists with expertise in transplant-related skin issues.

The increased incidence of KC in pediatric transplant recipients is “really high, so we definitely know there’s risk there,” just as there is for adult recipients of solid-organ transplants, said Cathryn Sibbald, MD, MSc, a dermatologist at the Hospital for Sick Children in Toronto and coauthor of a research letter published in June in JAMA Dermatology.

Cathryn Sibbald, MD, MSc, a dermatologist at The Hospital for Sick Children in Toronto

Dr. Cathryn Sibbald

For their study, Dr. Sibbald and her coinvestigators turned to the Ontario Health Insurance plan database, which covers health care for Canadian citizens and qualified residents in the province. They identified 951 patients younger than the age of 18 who received a solid-organ transplant between 1991 and 2004 at an Ontario hospital

They then used a validated health insurance claims–based algorithm to identify diagnoses of KC for the transplant recipients and for more than 5 million age-matched controls. KC, including squamous and basal cell carcinoma, is the most prevalent skin cancer for people who have had a solid-organ transplant.

Fifteen posttransplant KCs (10 patients, 1.1%) were reported a mean of 13.1 years after transplant, with none reported in the first 4 years. The mean age at transplant was 7.8 years, and the mean age at KC diagnosis was 25.2 years. Kidney transplants were the most common (42.1% of transplantations). Most of the transplants recipients (eight patients) who developed KC had kidney transplantation, and most of them had functional graft at the time of KC diagnosis.

Researchers found an increased incidence of KC compared with that of the general population (standardized incidence ratio, 9.09; 95% confidence interval, 5.48-15.08). And the risk for KC increased with time since transplant, with adjusted hazard ratios for KC of 3.63 (95% CI, 0.51-25.77) for 1-5 years, 5.14 (95% CI, 1.28-20.55) for 5-10 years, and 4.80 (95% CI, 2.29-10.08) for 10 years or more, compared with the control population.

Several years ago, another research team performed a similar population-based cohort study of adult transplant recipients in Ontario and found a 6.6-times increased risk of KC in transplant recipients compared with the general population.

Sun protection and skin cancer screening

In commenting on the study, Sarah Arron, MD, PhD, a San Francisco Bay area dermatologist and immediate past president of the International Immunosuppression and Transplant Skin Cancer Collaborative (www.itscc.org), said she feels “reassured” that young transplant patients tend not to develop the skin cancer until young adulthood.

Sarah Arron, MD, PhD, a San Francisco Bay area dermatologist

Dr. Sarah Arron

A ”large study like this is important because the overall rate of KC is low in this age group,” she noted.

The findings “suggest that we can focus our efforts on prevention during childhood, with sun protection and skin cancer education,” she said. “Then, as these children move into adulthood, we can begin screening with skin examinations. Of course, [any child] with a skin lesion or mole that concerns their parents or transplant team should be referred to dermatology for evaluation.”

Pediatric transplant recipients and their parents are most interested in learning about skin cancer prevention either before or immediately after transplantation, according to a survey by other researchers.

Pages

Recommended Reading

Why dermatologists should support artificial intelligence efforts
MDedge Hematology and Oncology
Study finds discrepancies in biopsy decisions, diagnoses based on skin type
MDedge Hematology and Oncology
PLA testing brings nuance to the diagnosis of early-stage melanoma
MDedge Hematology and Oncology
Which solid organ transplant recipients face the highest risk of skin cancer?
MDedge Hematology and Oncology
Q&A with Hubert (Hugh) Greenway, MD
MDedge Hematology and Oncology
Bupivacaine following Mohs surgery reduces opioid use, study finds
MDedge Hematology and Oncology
Studies address ibrutinib bleeding risk in patients with CLL receiving Mohs surgery
MDedge Hematology and Oncology
Adjunctive confocal microscopy found to reduce unnecessary skin excisions
MDedge Hematology and Oncology
Mohs surgery in the elderly: The dilemma of when to treat
MDedge Hematology and Oncology
Surgical site infections not increased in immunocompromised patients after Mohs surgery
MDedge Hematology and Oncology